Emergent BioSolutions Inc. (NYSE:EBS) Shares Acquired by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lifted its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 20.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 193,991 shares of the biopharmaceutical company’s stock after buying an additional 32,460 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.37% of Emergent BioSolutions worth $491,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Allspring Global Investments Holdings LLC grew its position in shares of Emergent BioSolutions by 1.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 460,289 shares of the biopharmaceutical company’s stock worth $1,105,000 after buying an additional 6,724 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Emergent BioSolutions by 52.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 19,867 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 6,823 shares during the period. Laurion Capital Management LP acquired a new position in Emergent BioSolutions in the third quarter worth $37,000. Jacobs Levy Equity Management Inc. boosted its holdings in Emergent BioSolutions by 0.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,246,020 shares of the biopharmaceutical company’s stock worth $4,236,000 after purchasing an additional 11,573 shares during the period. Finally, CoreCap Advisors LLC acquired a new position in Emergent BioSolutions in the fourth quarter worth $33,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Benchmark lifted their price objective on shares of Emergent BioSolutions from $5.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday, June 20th.

Emergent BioSolutions Stock Performance

Emergent BioSolutions stock opened at $6.90 on Wednesday. The company has a market cap of $361.30 million, a PE ratio of -0.63 and a beta of 1.62. The company has a fifty day moving average price of $4.71 and a two-hundred day moving average price of $3.12. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.08 and a quick ratio of 0.55. Emergent BioSolutions Inc. has a 12 month low of $1.42 and a 12 month high of $9.66.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.65) by $4.24. The company had revenue of $300.40 million during the quarter. Emergent BioSolutions had a negative net margin of 47.68% and a negative return on equity of 18.53%. During the same period last year, the firm posted ($3.17) EPS. Research analysts expect that Emergent BioSolutions Inc. will post -1.98 earnings per share for the current year.

Insider Transactions at Emergent BioSolutions

In other news, Director Kathryn C. Zoon sold 10,000 shares of the company’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $6.11, for a total transaction of $61,100.00. Following the completion of the transaction, the director now owns 54,482 shares in the company, valued at $332,885.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders sold 12,919 shares of company stock worth $75,831. Insiders own 1.20% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.